Welcome!

News Feed Item

Fc Protein and Glycoengineered Antibodies Market

DUBLIN, March 5, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/r8hfhg/fc_protein_and) has announced the addition of the "Fc Protein and Glycoengineered Antibodies Market" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Engineered antibodies are antibody based therapeutics, which are gaining increasing attention from both large and small pharmaceutical companies. Developed through introduction of modifications in monoclonal antibodies, the aim is to develop antibodies with improved efficacy.

Research done in the last decade to develop engineered antibodies has yielded a rich knowledge base on how to develop and market these next generation antibodies. These therapeutic antibodies seem to be more promising, with improved properties when compared to their ancestors. There are several molecules in phase II / III clinical trials and a few waiting for approvals. In addition, a large number of molecules are also in pre-clinical trials and are expected to progress through various stages of drug development over the next ten years.

The Fc Protein and Glycoengineered Antibody Market, 2013-2023 report was commissioned to examine the various aspects of engineering an antibody to develop novel drugs and address several oncology specific diseases. With the market being fairly new, the report examines several elements of developing these next generation antibodies including technologies used for their production, site of engineering in an antibody and molecules in pipeline.

For the purposes of this report, engineered antibodies are defined as antibodies which have been modified in their Fc region. The two types of modification considered are:

  • Fc Glycoengineering (referred to as Glycoengineering' in the report)
  • Fc Protein engineering

Key Topics Covered:

1. EXECUTIVE SUMMARY

2. INTRODUCTION

3. ENGINEERED ANTIBODIES: OVERVIEW AND BACKGROUND

4. GLYCOENGINEERED ANTIBODIES MARKET, 2012 - 2023

5. Fc PROTEIN ENGINEERED ANTIBODIES MARKET, 2013 - 2023

6. TECHNOLOGICAL PLATFORMS FOR ENGINEERED ANTIBODIES

7. PROFILES OF LEADING COMPANIES

8. SWOT ANALYSIS

9. CONCLUSIONS

10. APPENDIX 1: TABLES

11. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS


Companies Mentioned:

  • ABN AMRO Capital
  • AVID Bioservices
  • Absolute Antibody
  • Accurus Biosciences
  • Affitech A/S
  • Allos Therapeutics
  • Amgen
  • Andromeda Biotech
  • Applied Molecular Evolution (AME)
  • Astra Zeneca
  • BioMedinvest
  • BioWa
  • BioXcellence
  • BioXpress Therapeutics
  • Bioceros
  • Biocon
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • CSL
  • Celltrion
  • Centocor Ortho Biotech
  • Cephalon
  • ChemoCentryx
  • Chugai Pharmaceuticals
  • Deutsche Venture Capital
  • Diamyd Medical
  • Dong-A Pharmaceutical
  • Eli Lilly
  • Eureka Therapeutics
  • Five Prime Therapeutics
  • GSK
  • Genentech
  • Gilde Investment Management
  • Global Life Science Ventures
  • Glycart
  • Glycode
  • Glycotope
  • Green Cross Corporation
  • Greenovation
  • Halozyme Therapeutics
  • Hanwha Chemical
  • Human Genome Sciences
  • ISU Abxis
  • Ildong Pharmaceuticals
  • ImmunGene
  • Inhibrx
  • InvivoGen
  • KaloBios
  • Kyowa Hakko Kirin
  • Laboratoire français du Fractionnement et des Biotechnologies (LFB)
  • Life Science Pharmaceuticals
  • Lonza
  • MacroGenics
  • MedImmune
  • Meiji Seika Pharma
  • Mentrik Biotech
  • Merck-GlycoFi
  • Micromet
  • MilleGen
  • Minapharm Pharmaceuticals
  • Morphosys
  • Mylan
  • NKT Therapeutics
  • Nippon Kayaku
  • Nippon Shinyaku
  • Novartis
  • Novartis Venture Fund
  • Ortho-McNeil Janssen Pharmaceutical
  • PDL Biopharma
  • Pfizer
  • Pikamab
  • Pinnacle Oncology Hematology
  • PlantForm Corporation
  • ProStrakan
  • Quester Capital Management
  • Regeneron Pharmaceuticals
  • Roche
  • Sandoz
  • Sanofi
  • Schnell Biopharma
  • Seattle Genetics
  • Servier
  • Shanghai CP Guojian
  • SiaMedExpress
  • Sorrento Therapeutics
  • Synthon-Biolex
  • TG Therapeutics
  • Taiho Pharmaceutical
  • Teva Pharmaceuticals
  • Trubion
  • Vivalis
  • Watson Pharmaceuticals
  • WuXi AppTec
  • Xencor
  • Zymeworks
  • arGEN-X
  • biOasis Technologies
  • rEVO Biologic

For more information visit http://www.researchandmarkets.com/research/r8hfhg/fc_protein_and


Media Contact: Laura Wood , +353-1-481-1716, [email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
Daniel Jones is CTO of EngineerBetter, helping enterprises deliver value faster. Previously he was an IT consultant, indie video games developer, head of web development in the finance sector, and an award-winning martial artist. Continuous Delivery makes it possible to exploit findings of cognitive psychology and neuroscience to increase the productivity and happiness of our teams.
To Really Work for Enterprises, MultiCloud Adoption Requires Far Better and Inclusive Cloud Monitoring and Cost Management … But How? Overwhelmingly, even as enterprises have adopted cloud computing and are expanding to multi-cloud computing, IT leaders remain concerned about how to monitor, manage and control costs across hybrid and multi-cloud deployments. It’s clear that traditional IT monitoring and management approaches, designed after all for on-premises data centers, are falling short in ...
"Calligo is a cloud service provider with data privacy at the heart of what we do. We are a typical Infrastructure as a Service cloud provider but it's been designed around data privacy," explained Julian Box, CEO and co-founder of Calligo, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
In an era of historic innovation fueled by unprecedented access to data and technology, the low cost and risk of entering new markets has leveled the playing field for business. Today, any ambitious innovator can easily introduce a new application or product that can reinvent business models and transform the client experience. In their Day 2 Keynote at 19th Cloud Expo, Mercer Rowe, IBM Vice President of Strategic Alliances, and Raejeanne Skillern, Intel Vice President of Data Center Group and G...
With more than 30 Kubernetes solutions in the marketplace, it's tempting to think Kubernetes and the vendor ecosystem has solved the problem of operationalizing containers at scale or of automatically managing the elasticity of the underlying infrastructure that these solutions need to be truly scalable. Far from it. There are at least six major pain points that companies experience when they try to deploy and run Kubernetes in their complex environments. In this presentation, the speaker will d...
Discussions of cloud computing have evolved in recent years from a focus on specific types of cloud, to a world of hybrid cloud, and to a world dominated by the APIs that make today's multi-cloud environments and hybrid clouds possible. In this Power Panel at 17th Cloud Expo, moderated by Conference Chair Roger Strukhoff, panelists addressed the importance of customers being able to use the specific technologies they need, through environments and ecosystems that expose their APIs to make true ...
The current age of digital transformation means that IT organizations must adapt their toolset to cover all digital experiences, beyond just the end users’. Today’s businesses can no longer focus solely on the digital interactions they manage with employees or customers; they must now contend with non-traditional factors. Whether it's the power of brand to make or break a company, the need to monitor across all locations 24/7, or the ability to proactively resolve issues, companies must adapt to...
In his session at 20th Cloud Expo, Scott Davis, CTO of Embotics, discussed how automation can provide the dynamic management required to cost-effectively deliver microservices and container solutions at scale. He also discussed how flexible automation is the key to effectively bridging and seamlessly coordinating both IT and developer needs for component orchestration across disparate clouds – an increasingly important requirement at today’s multi-cloud enterprise.
Modern software design has fundamentally changed how we manage applications, causing many to turn to containers as the new virtual machine for resource management. As container adoption grows beyond stateless applications to stateful workloads, the need for persistent storage is foundational - something customers routinely cite as a top pain point. In his session at @DevOpsSummit at 21st Cloud Expo, Bill Borsari, Head of Systems Engineering at Datera, explored how organizations can reap the bene...
We are seeing a major migration of enterprises applications to the cloud. As cloud and business use of real time applications accelerate, legacy networks are no longer able to architecturally support cloud adoption and deliver the performance and security required by highly distributed enterprises. These outdated solutions have become more costly and complicated to implement, install, manage, and maintain.SD-WAN offers unlimited capabilities for accessing the benefits of the cloud and Internet. ...
In this presentation, you will learn first hand what works and what doesn't while architecting and deploying OpenStack. Some of the topics will include:- best practices for creating repeatable deployments of OpenStack- multi-site considerations- how to customize OpenStack to integrate with your existing systems and security best practices.
"DevOps is set to be one of the most profound disruptions to hit IT in decades," said Andi Mann. "It is a natural extension of cloud computing, and I have seen both firsthand and in independent research the fantastic results DevOps delivers. So I am excited to help the great team at @DevOpsSUMMIT and CloudEXPO tell the world how they can leverage this emerging disruptive trend."
Security, data privacy, reliability and regulatory compliance are critical factors when evaluating whether to move business applications from in-house client hosted environments to a cloud platform. In her session at 18th Cloud Expo, Vandana Viswanathan, Associate Director at Cognizant, In this session, will provide an orientation to the five stages required to implement a cloud hosted solution validation strategy.